Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Engineering of a temperate Burkholderia cepacia complex phage to improve efficacy as a potential therapeutic

Award Number: R21AI194149
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/10/2026
PERIOD OF PERFORMANCE END DATE: 05/31/2028

Group Awards By:

View Award Description

Engineering of a temperate Burkholderia cepacia complex phage to improve efficacy as a potential therapeutic - Project Summary Bacteria in the Burkholderia cepacia complex (Bcc) cause difficult to treat infections in patients with compromised respiratory systems, such as those with cystic fibrosis (CF). Alternative treatment options are needed, since antibiotics often fail these patients. Bacteriophage (phage) therapy is a promising strategy, yet therapeutically ideal phages are difficult to find and narrow in their range of use due to host specificity. In the proposed study, we continue development of a potential phage therapeutic sourced from Burkholderia itself. We have isolated a phage, called BCC02, that was present within the genome of a Burkholderia bacteria (a prophage) and have shown that it can kill other bacteria within the same genus. However, this phage still has the potential to integrate into other bacterial genomes, which is an undesirable trait for phage therapy. By engineering changes to the BCC02 genome using synthetic biology techniques, we hypothesize that we can increase its range of therapeutic potential by disabling its ability to integrate into the bacterial genome, and that this change will increase the number of bacteria that it can lyse. The specific aims of this project are to (1) engineer this phage to lose the ability to lysogenize (integrate into bacterial genomes) then test the effects of these modifications on bacterial host range and (2) test activity of our originally isolated phage, BCC02 as well as our engineered variant on a clinically relevant panel of patho-adapted isolates from patients with CF. We propose to use transformation-associated recombination (TAR) cloning methods to target the lysogeny control region of the BCC02 genome for removal. We hypothesize that loss of integration ability will force this phage into an obligately lytic lifestyle, where it will lyse all bacteria it is able to infect. Successful completion of this project will determine the feasibility of engineering obligately lytic Burkholderia-targeting phages from Burkholderia spp. prophages, shed light on the effects of lytic lifestyle on host range, and establish the utility of these phages for tackling particularly problematic clinical infections. In addition, this study may produce a Bcc- targeting phage that is primed for development to be used for phage therapy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $529,490 )
2026	2026	J. CRAIG VENTER INSTITUTE, INC.	4120 CAPRICORN LN	LA JOLLA	CA	92037	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	1	6/11/2026	NEW	$529,490
														Subtotal = $529,490

Grand Total All Awards = $529,490

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Engineering of a temperate Burkholderia cepacia complex phage to improve efficacy as a potential therapeutic

Award Number: R21AI194149

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/10/2026

PERIOD OF PERFORMANCE END DATE: 05/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer